Home›Trial›NCT05567185
🔬NCT05567185Phase 1ACTIVE NOT RECRUITING

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Study Summary

The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.

Conditions
Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
Interventions / Drugs
Erdafitinib Intravesical Delivery System
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment5 participants
Primary Completion—
Lead SponsorJanssen Pharmaceutical K.K.
Data Retrieved2026-04-11 02:55:31.550309+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.